Drug Trial Radar · NCT03354273
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
Last checked: Nov 20, 2026Latest source record: Jul 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
730
Actual
Start
Jun 5, 2018
Primary completion
May 5, 2022
Study completion May 5, 2022
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- Pharmaceutical Product Development, (PPD) LLC
- First posted
- Nov 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
Conditions
- Coronary Artery Disease (CAD)
Interventions
PET MPIDrug
Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
SPECT MPIDrug
SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
Pharmacological stress agentsDrug
Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary Artery Disease (CAD) as Defined by Cardiac CatheterizationTime frame: Up to 60 days
Locations
53 sites in 7 countries. Site status is shown where the registry gives one.
Vascular Biology and Hypertension Program, University of Alabama at Birmingham
Birmingham, Alabama
University of California- Los Angeles
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
VA Greater Los Angeles Health Care System
Los Angeles, California
VA San Diego Health System
San Diego, California
UCSF
San Francisco, California
Tower Saint John's Imaging
Santa Monica, California
Yale New Haven Hospital
New Haven, Connecticut
Cardiology Physicians PA/Red Clay Research LLC
Newark, Delaware
University of Florida
Gainesville, Florida
Indago Research and Health Center
Hialeah, Florida
Optimus U Corp
Miami, Florida
Infinite Clinical Research
Miami, Florida
Allied Biomedical Research Institute
Miami, Florida
Comprehensive Vascular Care PA
Miami, Florida
Amavita Clinical Research, LLC
North Miami Beach, Florida
Emory University
Atlanta, Georgia
University Of Iowa Hospitals And Clinics
Iowa City, Iowa
Midwest Heart and Vascular Specialists
Overland Park, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
VA St. Louis Health Care System
St Louis, Missouri
St Louis University
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center/New York Presbyterian Hospital - Milstein Hospital Building
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
OhioHealth Research Institute
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Berks Cardiologists, LTD
Wyomissing, Pennsylvania
University of Tennessee Medical Center
Knoxville, Tennessee
VA North Texas Health Care System - NAVREF - PPDS
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
The Methodist Hospital Research Institute
Houston, Texas
Vital Heart & Vein
Humble, Texas
Memorial City and Katy Cardiology Associates
Katy, Texas
University of Virginia Health System
Charlottesville, Virginia
Roanoke Heart Institute
Roanoke, Virginia
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Center Hospitalier Universitaire de Sherbrooke CHUS
Montreal, Quebec, Canada
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.